gsk201605036k3.htm

SECURITIES AND EXCHANGE COMMISSION 

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of 

the Securities Exchange Act of 1934

For period ending 03 May 2016

(Name of registrant) 

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices) 

Indicate by check mark whether the registrant files or

will file annual reports under cover Form 20-F or Form 40-F 

Form 20-F x Form 40-F 

Indicate by check mark whether the registrant by furnishing the

information contained in this Form is also thereby furnishing the

information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934. 

GlaxoSmithKline plc

(the "Company")

Notification of Transactions of Directors, Persons Discharging Managerial Responsibilities or Connected Persons

In accordance with DTR 3.1.4 R (1) (a), I give details of changes in the interests in the Company's Ordinary Shares of 25p each ("Ordinary Shares") for Ms Claire Thomas, a Person Discharging Managerial Responsibilities, following the sale of 30,000 Ordinary Shares on 3 May 2016 at a price of £14.59 per Ordinary Share.

The Company and Ms Thomas were advised of this transaction on 3 May 2016.

V A Whyte

Company Secretary

3 May 2016

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised. 

----------------------

Authorised Signatory for and on

behalf of GlaxoSmithKline plc